News Agency
The Times

VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism

  • Written by PR Newswire
  • 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primary multi-component endpoint compared to 0.0% for placebo (p <0.0001)
  •  Palopegteriparatide was generally safe and well-tolerated, with no discontinuations related to study drug.

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- VISEN Pharmaceuticals, an...

Read more: VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion